ChromaDex (NASDAQ:CDXC) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of ChromaDex (NASDAQ:CDXC) in a research report report published on Sunday. The firm issued a buy rating on the stock.

A number of other brokerages have also weighed in on CDXC. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of ChromaDex in a research note on Monday, March 17th. LADENBURG THALM/SH SH raised their price objective on shares of ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a research report on Wednesday, March 5th.

ChromaDex Price Performance

The company’s fifty day simple moving average is $6.16 and its two-hundred day simple moving average is $5.44. ChromaDex has a twelve month low of $2.31 and a twelve month high of $9.18. The firm has a market cap of $611.50 million, a PE ratio of 787.29 and a beta of 2.21.

Institutional Investors Weigh In On ChromaDex

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC increased its position in ChromaDex by 322.1% in the third quarter. Barclays PLC now owns 70,072 shares of the company’s stock worth $256,000 after purchasing an additional 53,472 shares during the period. Sargent Investment Group LLC acquired a new stake in shares of ChromaDex during the 4th quarter worth approximately $263,000. JPMorgan Chase & Co. grew its position in shares of ChromaDex by 11.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock worth $1,211,000 after buying an additional 33,150 shares during the period. FMR LLC bought a new stake in shares of ChromaDex during the third quarter worth approximately $55,000. Finally, State Street Corp lifted its holdings in ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after buying an additional 62,692 shares during the period. Institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.